Trials / Completed
CompletedNCT03221881
Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer
The Effectiveness and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Breast Cancer.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
In this study, PLD, an anthracycline encapsulated in stealth liposomes, which are believed to efficiently deliver the doxorubicin within the tumour mass with less toxicity compared with standard doxorubicin formulation was used. The study aimed to determine whether the combination of PLD-docetaxel would increase tumour response in patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Liposomal Doxorubicin and docetaxel |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2017-04-01
- Completion
- 2017-06-01
- First posted
- 2017-07-19
- Last updated
- 2017-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03221881. Inclusion in this directory is not an endorsement.